Remove tag leadership
article thumbnail

Grand Rounds December 15, 2023: Diversifying Clinical Trials: A Path Forward (Roxana Mehran, MD, FACC, FAHA, MSCAI, FESC)

Rethinking Clinical Trials

Increasing diversity in trial leadership is one of the most important strategies to increase diversity among RCT participants. Approaches from the whole scientific community to tackle the inequality in workforce, trial leadership and trial participants have to be developed. We need to think about removing some of this and evaluate.

article thumbnail

Grand Rounds January 26, 2024: Advancing the Safe, Effective and Equitable Use of AI in Healthcare (Mark Sendak, MD, MPP; Suresh Balu, MD, MBA)

Rethinking Clinical Trials

DIHI approaches this work through four pillars of innovation: implementation and health delivery science, health technology innovation, leadership and workforce development, and best practices development and dissemination. . – How do you get reliable information and data for care that is received outside of Duke?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds October 28, 2022: The HERO (Healthcare Worker Exposure Response & Outcomes) Program: An Online Community to Support Observational Studies, Randomized Trials, and Long-Term Safety Surveillance (Emily O’Brien, PhD, FAHA; Russell Rothman, MD, MPP)

Rethinking Clinical Trials

On March 21, 2020, in response to the COVID-19 pandemic, PCORI contacted leadership at Duke Clinical Research Institute and PCORnet and a decision was made to focus on the space of healthcare workers. HERO Registry; HERO TOGETHER; Hydroxychloroquine; COVID-19; PCORI; PCORnet. Key Points. pctGR, @Collaboratory1.

Trials 130
article thumbnail

Grand Rounds June 16, 2023: BeatPain Utah: Partnering With Community Health Centers Within a Socio-Technical Framework (Julie Fritz, PT, PhD, FAPTA; Guilherme Del Fiol, MD, PhD)

Rethinking Clinical Trials

Another crucial element of the health equity–focused model is ensuring that the question at the heart of the research is of value to the clinics and their leadership. For every trial, one of the first important tasks is to reach out to the community health center leadership and see if they are interested.

article thumbnail

Grand Rounds Ethics and Regulatory Series September 9, 2022: Building An Academic Learning Health System: Why Is It So Hard? (Steven Joffe, MD, MPH)

Rethinking Clinical Trials

Academic medical institutions may seem like the natural setting to build Learning Health Systems (LHS), but they face unique structural barriers that require leadership, focus, and intentionality to overcome. It requires leadership, focus and intentionality making it central to the mission of the organization. Key Points. Learn more.

article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Joanna Carlish, managing director, financial services, Tag Americas. Virtual connections.

article thumbnail

bluebird bio to split into oncology and gene therapy specialists

pharmaphorum

Meanwhile the as-yet unnamed oncology company will spin off under the leadership of bluebird’s current chief executive Nick Leschly. million price tag. Under the plans the company’s rare disease drugs will remain under the aegis of bluebird with current genetic disease president Andrew Obenshain taking the reins as CEO.